Quarterly ResultMay 12, 2026, 08:17 AM
ProMIS Neurosciences Raises $70.1M in PIPE; Cash Jumps to $63.8M
AI Summary
ProMIS Neurosciences reported its Q1 2026 financial results, highlighting a significant increase in its cash position due to a private placement. The company secured $70.1 million in net proceeds from a January 2026 PIPE offering, boosting cash to $63.8 million by March 31, 2026, up from $6.1 million at year-end 2025. Despite an increased net loss of $8.2 million for the quarter, the company expects its current capital to fund operations through 2027, though additional funding will be required for future clinical activities.
Key Highlights
- Net proceeds from January 2026 PIPE financing totaled $70.1 million.
- Cash increased to $63.8 million as of March 31, 2026, from $6.1 million at Dec 31, 2025.
- Net loss for Q1 2026 was $(8.2) million, compared to $(7.3) million in Q1 2025.
- Net loss per share for Q1 2026 was $(1.26), an improvement from $(5.27) in Q1 2025.
- Research and development expenses rose to $7.0 million in Q1 2026 from $5.5 million in Q1 2025.
- Net cash used in operating activities was $(12.4) million in Q1 2026, up from $(4.9) million in Q1 2025.
- Existing cash and investments are expected to fund operations through 2027.
- 8,967,693 common shares were issued and outstanding as of March 31, 2026.